Anti-DDAH1 antibody (ab2231)
Key features and details
- Goat polyclonal to DDAH1
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-DDAH1 antibody
See all DDAH1 primary antibodies -
Description
Goat polyclonal to DDAH1 -
Host species
Goat -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Cow
-
Immunogen
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
pH: 7.30
Preservative: 0.02% Sodium azide
Constituents: Tris buffered saline, 0.5% BSA -
Concentration information loading... -
Purity
Immunogen affinity purified -
Purification notes
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab2231 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | (3) |
Use a concentration of 0.1 - 0.3 µg/ml. Detects a band of approximately 35 kDa (predicted molecular weight: 31 kDa).
1 hour primary incubation is recommended for this product. |
| Notes |
|---|
|
WB
Use a concentration of 0.1 - 0.3 µg/ml. Detects a band of approximately 35 kDa (predicted molecular weight: 31 kDa). 1 hour primary incubation is recommended for this product. |
Target
-
Function
Hydrolyzes N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-monomethyl-L-arginine (MMA) which act as inhibitors of NOS. Has therefore a role in the regulation of nitric oxide generation. -
Tissue specificity
Detected in brain, liver, kidney and pancreas, and at low levels in skeletal muscle. -
Sequence similarities
Belongs to the DDAH family. - Information by UniProt
-
Database links
- Entrez Gene: 23576 Human
- Omim: 604743 Human
- SwissProt: P56965 Cow
- SwissProt: O94760 Human
- Unigene: 379858 Human
- Unigene: 713411 Human
-
Alternative names
- DDAH antibody
- DDAH I antibody
- DDAH-1 antibody
see all
Images
-
Western blot - Anti-DDAH1 antibody (ab2231)Anti-DDAH1 antibody (ab2231) at 0.100000001490116 µg/ml + Human kidney lysate at 35 µg
Predicted band size: 31 kDa
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (14)
ab2231 has been referenced in 14 publications.
- Zhu ZD et al. DDAH2 alleviates myocardial fibrosis in diabetic cardiomyopathy through activation of the DDAH/ADMA/NOS/NO pathway in rats. Int J Mol Med 43:749-760 (2019). PubMed: 30569164
- Joris V et al. MicroRNA-199a-3p and MicroRNA-199a-5p Take Part to a Redundant Network of Regulation of the NOS (NO Synthase)/NO Pathway in the Endothelium. Arterioscler Thromb Vasc Biol 38:2345-2357 (2018). PubMed: 29976767
- Balasubramanian V et al. Post-Transcriptional Regulation of Hepatic DDAH1 with TNF Blockade Leads to Improved eNOS Function and Reduced Portal Pressure In Cirrhotic Rats. Sci Rep 7:17900 (2017). WB ; Rat . PubMed: 29263339
- Hulin JA et al. MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1. Sci Rep 7:13996 (2017). PubMed: 29070803
- Mookerjee RP et al. Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. J Hepatol 62:325-31 (2015). WB, IHC ; Human . PubMed: 25152204